GYRE THERAPEUTICS, INC. annual report, FY2011

Business context and reporting period

This is Targacept, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 6, 2012. The request metadata names GYRE THERAPEUTICS, INC., but the filing identifies Targacept, Inc.; confirm the issuer and filing match your intended company. Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor (NNR) therapies and had no product revenue in 2011. Its principal collaborations were with AstraZeneca.

Financial performance and position

Revenue was primarily collaboration-related: $97.0 million from collaboration license fees and milestones and $0.7 million from grants. No product sales were reported. Revenue recognition included substantial previously received, deferred collaboration payments, rather than corresponding current-period cash receipts. The 2010 profit likewise reflected recognition of collaboration revenue, including the AstraZeneca upfront payment.

At year-end, cash, cash equivalents and investments totaled $249.3 million; working capital was $120.1 million; total assets were $258.1 million; and total liabilities were $83.8 million. Debt was approximately $3.2 million in balance-sheet principal ($1.2 million current and $2.0 million long-term). The company raised $80.8 million net through a 2011 stock offering. Accumulated deficit was $226.9 million. The filing reported no gross margin measure applicable to 2011, as there were no product sales.

Material changes versus the prior comparable period

• Revenue increased $11.9 million, but operating results shifted from $13.1 million of operating income to a $9.7 million operating loss; net results shifted from $10.9 million of income to an $8.5 million loss.
• R&D expense rose $30.7 million, principally from TC-5214 Phase 3 cost sharing and expanded clinical-stage programs. TC-5214 third-party development costs were $32.0 million in 2011 versus $10.8 million in 2010.
• Operating cash flow fell from $138.3 million provided to $83.7 million used. The 2010 figure included the $200 million AstraZeneca upfront payment; 2011 cash use reflected development spending.
• GlaxoSmithKline terminated its collaboration effective May 2011. Targacept recognized $18.4 million of remaining deferred GSK revenue in first-quarter 2011; the arrangement is no longer a source of future funding.
• TC-5214’s first two completed Phase 3 adjunct-treatment trials failed to meet their primary endpoint, and the company’s stock price fell sharply following the November 2011 results announcement.

Outlook, commentary, risks and unusual items

• Management expected existing capital resources to fund operations through at least year-end 2014, excluding potential AstraZeneca milestones; it cautioned that changed plans or development needs could require earlier funding. Management expected 2012 R&D expense to decrease, principally because the planned TC-5214 Phase 3 program was expected to finish in the first half of 2012.
• Two additional TC-5214 Phase 3 adjunct trials and a long-term safety study were ongoing; a Phase 2b switch-monotherapy trial was also ongoing. Management expected these studies to complete during 2012, but timing and results were uncertain. TC-5214’s potential U.S. five-year new-chemical-entity exclusivity depended on statutory and filing conditions, including a September 30, 2012 deadline described in the filing.
• Other programs included TC-5619 Phase 2 studies in schizophrenia and inattentive ADHD; AZD3480 Phase 2b in Alzheimer’s disease; TC-6987 Phase 2 studies in asthma and Type 2 diabetes; and AstraZeneca’s planned progression of AZD1446 in Alzheimer’s disease. Earlier studies had mixed or inconclusive findings; the current studies remained unproven.
• Collaboration dependence is material: AstraZeneca controls or significantly influences development decisions for licensed candidates and may terminate the cognitive-disorders agreement on 90 days’ notice. Its February 2012 R&D restructuring added uncertainty about AZD1446 and potential further AZD3480 development.
• Other key risks include clinical failure or delay, regulatory uncertainty, reliance on third-party manufacturers and trial operators, intellectual-property challenges, reimbursement and competition, and potential need for additional capital. Contractual obligations totaled $31.8 million, including $26.3 million of purchase obligations; these do not include Targacept’s anticipated TC-5214 cost share. The office lease was due to expire July 31, 2012, with extension discussions ongoing.
• The company reported no material pending legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.

Most important facts for investors to verify

1. Confirm the issuer identity: this filing is for Targacept, Inc., not GYRE THERAPEUTICS, INC.
2. Check subsequent results and regulatory developments for the remaining TC-5214 trials, the switch study, and any NDA filing or acceptance.
3. Assess the quality and sustainability of reported revenue: FY 2011 revenue depended overwhelmingly on collaboration accounting and grants, not product sales or recurring commercial revenue.
4. Verify current cash runway against operating cash burn, clinical commitments, milestone assumptions, and any subsequent financing or pipeline reprioritization.
5. Review AstraZeneca’s post-restructuring development decisions and the terms and potential consequences of collaboration termination.